NCT02296125 2026-01-09
FLAURA
AstraZeneca
Phase 3 Completed
Clinical Trials
67 trialsNCT03653546 2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT04179890 2023-05-25
UpSwinG
Boehringer Ingelheim
Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT02088112 2022-04-04
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
MedImmune LLC
Phase 1 Completed
NCT01610336 2021-04-08
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Phase 2 Completed
NCT02374645 2020-04-24
A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
Hutchmed
Phase 1 Completed
NCT01466660 2020-04-07
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
Phase 2 Completed
NCT02976116 2019-11-15
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT01469000 2019-09-10
A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed
NCT02179671 2019-08-02
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT01203917 2017-01-02
IFUM
AstraZeneca
Phase 4 Completed
NCT00059722 2016-08-24
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
Sanofi
Phase 2 Completed
NCT00259064 2016-06-02
INSTEP
AstraZeneca
Phase 2/3 Completed
NCT01530334 2016-02-23
ICARUS
AstraZeneca
Phase 2 Completed
NCT00770588 2016-02-08
INFORM
AstraZeneca
Phase 4 Completed
NCT00162318 2015-10-28
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00229697 2015-10-05
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
AstraZeneca
Phase 2 Completed
NCT01017874 2015-07-08
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed
NCT01602289 2015-06-08
A Study of LY2875358 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01039948 2015-04-08
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00077025 2014-07-16
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
AstraZeneca
Phase 2 Completed
NCT01040780 2014-02-14
ICOGEN
Betta Pharmaceuticals Co., Ltd.
Phase 3 Completed
NCT00265070 2013-02-05
Trial of Iressa in Prostate Cancer Patients
AstraZeneca
Phase 2 Completed
NCT00034879 2013-01-04
Iressa Expanded Access Program (EAP)
AstraZeneca
Phase 3 Completed
NCT00608868 2012-09-28
SELINE
AstraZeneca
Phase 4 Completed
NCT00478049 2012-06-06
ISTANA
AstraZeneca
Phase 3 Completed
NCT00787410 2012-06-06
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
AstraZeneca
Phase 2 Completed
NCT00113529 2011-08-29
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
Pfizer
Phase 1/2 Completed
NCT00076388 2011-05-13
Iressa Versus Docetaxel (Taxotere)
AstraZeneca
Phase 3 Completed
NCT00206219 2011-01-27
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
AstraZeneca
Phase 3 Completed
NCT00239343 2011-01-27
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00242762 2011-01-27
ZD1839 (IRESSAâ„¢) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
AstraZeneca
Phase 2 Completed
NCT00255489 2011-01-25
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
AstraZeneca
Phase 1 Completed
NCT00319787 2011-01-25
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
AstraZeneca
Phase 2 Completed
NCT00238797 2011-01-21
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
AstraZeneca
Phase 2 Completed
NCT00409006 2010-09-09
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
Eli Lilly and Company
Phase 2 Completed
NCT00344773 2010-06-29
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
AstraZeneca
Phase 2 Completed
NCT00229723 2009-08-04
IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00264498 2009-08-03
Phase II Iressa & Carbo/Gem in NSCLC
AstraZeneca
Phase 2 Completed
NCT00502060 2009-05-14
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
AstraZeneca
Phase 1 Completed
NCT00127829 2009-04-23
AGUS
AstraZeneca
Phase 1 Completed
NCT00234403 2009-04-23
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00234416 2009-04-23
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
AstraZeneca
Phase 1/2 Completed
NCT00239291 2009-04-23
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
AstraZeneca
Phase 1/2 Completed
NCT00241475 2009-04-23
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
AstraZeneca
Phase 2 Completed
NCT00242749 2009-04-23
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
AstraZeneca
Phase 2 Completed
NCT00242788 2009-04-23
IRESSAâ„¢ In Combo With Xelodaâ„¢ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
AstraZeneca
Phase 1/2 Completed